Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
SOF/VEL/VOX effectief en veilig bij hepatitis C na falen op DAA’s
mrt 2020 | Hepatitis